Cingulate (NASDAQ:CING) Now Covered by Analysts at Roth Mkm

Roth Mkm assumed coverage on shares of Cingulate (NASDAQ:CING) in a research note released on Friday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $12.00 price target on the stock.

Separately, Maxim Group raised Cingulate from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th.

Cingulate Stock Up 11.6 %

CING opened at $4.81 on Friday. The business’s fifty day simple moving average is $4.36 and its 200 day simple moving average is $4.10. Cingulate has a 52 week low of $1.80 and a 52 week high of $88.44.

Cingulate (NASDAQ:CING) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.22) by $0.39. On average, equities analysts expect that Cingulate will post -9.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cingulate stock. Armistice Capital LLC purchased a new position in shares of Cingulate Inc. (NASDAQ:CING) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 490,000 shares of the company’s stock, valued at approximately $157,000. Armistice Capital LLC owned about 6.67% of Cingulate as of its most recent filing with the Securities and Exchange Commission (SEC). 41.31% of the stock is currently owned by institutional investors.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.